AR023911A1 - Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma - Google Patents

Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Info

Publication number
AR023911A1
AR023911A1 ARP990105443A ARP990105443A AR023911A1 AR 023911 A1 AR023911 A1 AR 023911A1 AR P990105443 A ARP990105443 A AR P990105443A AR P990105443 A ARP990105443 A AR P990105443A AR 023911 A1 AR023911 A1 AR 023911A1
Authority
AR
Argentina
Prior art keywords
effector
bronchodilator
pharmaceutical composition
prepare
sulfated polysaccharide
Prior art date
Application number
ARP990105443A
Other languages
English (en)
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of AR023911A1 publication Critical patent/AR023911A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion farmacéutica para tratar el asma y patologías relacionadas en un mamífero, que comprende cantidades terapéuticamente efectivas de unbroncodilatador y un efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 aalrededor de 10 residuos de azucar. La composicion puedecomprender además un portador farmacéuticamente aceptable. Preferentemente, el broncodilatador es un agonista adrenérgico beta2 seleccionado del grupointegrado por salmeterol, formoterol, bambuterol, albuterol, terbutalina, pirbuterol, bitolterol, metaproterenol, isoetarina e isoproterenol. En formapreferida, el efector es un polisacárido N-sulfatado, como por ejemplo la heparina que puede ser una heparina de peso molecular ultra bajo (ULMWH) o unaheparina de bajo peso molecular (LMWH). Uso de un broncodilatador y un efector para preparar una composicion farmacéutica de utilidad en un método paraprevenir la tolerancia al broncodilatador en un mamífero que lo necesite, y que comprendela administracion de cantidades terapéuticamente efectivas delbroncodilatador y del efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 a alrededor de 10 residuos de azucar. De esta manera sepuede prevenir la tolerancia alos mencionados agonistas adrenérgicos beta2, empleados como broncodilatadores.
ARP990105443A 1998-10-30 1999-10-28 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma AR023911A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10650798P 1998-10-30 1998-10-30
US09/362,540 US6235725B1 (en) 1998-10-30 1999-07-28 Methods and compositions for the prevention of tolerance to medications

Publications (1)

Publication Number Publication Date
AR023911A1 true AR023911A1 (es) 2002-09-04

Family

ID=26803748

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105443A AR023911A1 (es) 1998-10-30 1999-10-28 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma
ARP110103258A AR082913A2 (es) 1998-10-30 2011-09-07 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110103258A AR082913A2 (es) 1998-10-30 2011-09-07 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Country Status (25)

Country Link
US (1) US6235725B1 (es)
EP (1) EP1124563B1 (es)
JP (1) JP4585121B2 (es)
CN (2) CN100352448C (es)
AR (2) AR023911A1 (es)
AT (1) ATE277621T1 (es)
AU (1) AU760119B2 (es)
BR (1) BR9915818A (es)
CA (1) CA2348926C (es)
CO (1) CO5160320A1 (es)
CY (1) CY1107493T1 (es)
CZ (1) CZ297914B6 (es)
DE (1) DE69920734T2 (es)
ES (1) ES2228173T3 (es)
HK (1) HK1041596A1 (es)
HU (1) HUP0302492A3 (es)
IL (2) IL142865A0 (es)
IS (1) IS2321B (es)
NO (1) NO333194B1 (es)
NZ (1) NZ511399A (es)
PL (1) PL195592B1 (es)
PT (1) PT1124563E (es)
SK (1) SK285150B6 (es)
TW (1) TW565451B (es)
WO (1) WO2000025723A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DZ3477A1 (es) * 2000-10-12 2002-04-18
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
CA2516318C (en) * 2002-02-18 2011-07-19 University Of Southampton Use of glycosaminoglycans such as heparin for the treatment of respiratory disorders such as copd
EP1513502B1 (en) * 2002-02-18 2015-12-30 Ockham Biotech Limited Combination therapy for respiratory disorders
CA2516322C (en) * 2002-02-18 2013-10-15 University Of Southampton Glycosaminoglycan-dnase combination therapy
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
JP4851185B2 (ja) 2003-05-16 2012-01-11 ジェレックスインターナショナル株式会社 アレルギー症状抑制剤及び空気濾過フィルター
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
KR20160022404A (ko) 2005-09-14 2016-02-29 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
WO2011133687A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104069497A (zh) * 2014-06-27 2014-10-01 东莞市凯法生物医药有限公司 一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20190070244A1 (en) * 2017-06-30 2019-03-07 The New Zealand Institute For Plant And Food Research Limited Boysenberry compositions and methods of preparation and use thereof
CA3070571A1 (en) 2017-08-08 2019-02-14 Odette M. Shaw Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
ES2079210T3 (es) 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
CZ20011518A3 (cs) 2002-04-17
NO20012097L (no) 2001-06-15
CA2348926C (en) 2011-08-23
JP2002535245A (ja) 2002-10-22
CY1107493T1 (el) 2013-03-13
US6235725B1 (en) 2001-05-22
EP1124563B1 (en) 2004-09-29
HUP0302492A2 (hu) 2003-11-28
HK1041596A1 (zh) 2002-07-12
HUP0302492A3 (en) 2005-05-30
CN100352448C (zh) 2007-12-05
CO5160320A1 (es) 2002-05-30
DE69920734T2 (de) 2005-10-06
EP1124563A4 (en) 2002-01-02
NZ511399A (en) 2004-09-24
BR9915818A (pt) 2002-06-18
IL142865A (en) 2006-07-05
IL142865A0 (en) 2002-03-10
AU760119B2 (en) 2003-05-08
CN1329496A (zh) 2002-01-02
IS5928A (is) 2001-04-27
ES2228173T3 (es) 2005-04-01
ATE277621T1 (de) 2004-10-15
NO20012097D0 (no) 2001-04-27
AR082913A2 (es) 2013-01-16
DE69920734D1 (de) 2004-11-04
IS2321B (is) 2007-12-15
CN1572303A (zh) 2005-02-02
CA2348926A1 (en) 2000-05-11
CZ297914B6 (cs) 2007-04-25
WO2000025723A3 (en) 2000-07-27
TW565451B (en) 2003-12-11
AU1205100A (en) 2000-05-22
SK285150B6 (sk) 2006-07-07
EP1124563A2 (en) 2001-08-22
NO333194B1 (no) 2013-04-02
SK5902001A3 (en) 2002-07-02
PL364727A1 (en) 2004-12-13
WO2000025723A2 (en) 2000-05-11
PL195592B1 (pl) 2007-10-31
JP4585121B2 (ja) 2010-11-24
PT1124563E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
AR023911A1 (es) Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma
James Fractures of the proximal and middle phalanges of the fingers
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
ATE233084T1 (de) Pharmazeutische aerosolformulierung
PT915910E (pt) Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
BR9714059A (pt) S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
BR9808641B1 (pt) processo para preparação de uma forma de dosagem sólida, oral de rápida desintegração de uma substáncia farmaceuticamente ativa que possui um sabor inaceitável.
GB2385524A (en) Compositions and methods of use for extracts of magnoliaceae
YU73600A (sh) Novi nukleosidi koji imaju biciklične šećerne grupe
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
AR019681A1 (es) Una formulacion conservante de amplio espectro, un metodo para preparar la formulacion conservante, una solucion de yodo propinilo estabilizadora y un procedimiento para destruir o retardar el crecimiento de procedimiento para destruir o retardar el crecimiento de microbios
BRPI0110947B8 (pt) processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida
ES512464A0 (es) Un procedimiento para la preparacion de un nuevo antitrombosico a base de oligosacaridos y polisacaridos.
BR9005572A (pt) Sulfonilaminocarboniltriazolinon as com substituintes ligados atraves do enxofre,processo para sua preparacao,composicoes herbicidas,aplicacao,processo para combater ervas daninhas,processo para a preparacao de composicoes herbicidas e derivados de triazolinona
ES2144404T3 (es) Union de piezas huecas, asi como procedimiento para su fabricacion.
Fiaud Theory and practice of vapour phase inhibitors
AR030047A1 (es) Una composicion de poliisocianato liquida y un proceso para prepararla
BR9914815A (pt) Composições para tratamento e prevenção de doenças cardiovasculares
NZ218175A (en) Prazosin-pirbuterol combination for bronchodilation
RU2226103C2 (ru) Способы и композиции для предотвращения развития толерантности к лекарственным средствам
KR910015697A (ko) 한약재를 원료로한 보양주의 제조방법

Legal Events

Date Code Title Description
FC Refusal